Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by Barnett & Company Inc.

Barnett & Company Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 213,625 shares of the biopharmaceutical company’s stock after purchasing an additional 11,970 shares during the quarter. Pfizer makes up approximately 4.1% of Barnett & Company Inc.’s holdings, making the stock its 7th biggest position. Barnett & Company Inc.’s holdings in Pfizer were worth $6,182,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Marshall Wace LLP increased its holdings in Pfizer by 279.3% during the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after buying an additional 8,378,173 shares during the last quarter. Swedbank AB purchased a new stake in shares of Pfizer in the 1st quarter worth $172,902,000. International Assets Investment Management LLC bought a new position in Pfizer in the 3rd quarter worth $146,481,000. 1832 Asset Management L.P. lifted its position in Pfizer by 24,961.6% during the second quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after purchasing an additional 2,487,919 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Pfizer by 120.7% during the third quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock valued at $130,181,000 after purchasing an additional 2,459,666 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.08 during mid-day trading on Tuesday, reaching $26.16. The stock had a trading volume of 16,869,348 shares, compared to its average volume of 37,560,887. The business’s 50 day moving average price is $28.84 and its 200 day moving average price is $28.67. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a market cap of $148.25 billion, a P/E ratio of 35.32, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the company earned ($0.17) EPS. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.42%. Pfizer’s payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.